On July 28, Johnson & Johnson rose 5.28% in after-hours trading, trading at approximately $275.36/share, with turnover of $104 million.

On the news front, the company's OTTAVA robotic surgical system received FDA De Novo marketing authorization, establishing a new category of table-integrated soft tissue surgical robots. The system is approved for ten general surgery indications in the upper abdomen, including Roux-en-Y gastric bypass, gastrectomy, cholecystectomy, and splenectomy. Management stated OTTAVA represents not just a hardware iteration but a revolution in surgical care models, with a phased commercial launch planned for select US customers.

Additionally, Johnson & Johnson disclosed that its talc-related litigation settlement will involve a maximum first payment of $3 billion in 2027, with no additional payment obligations before 2028. The company's Q2 results previously beat expectations with adjusted EPS of $2.90 versus the $2.85 estimate and revenue of $25.31 billion versus $25.05 billion expected, while raising full-year adjusted EPS guidance midpoint to $11.68. Multiple analysts subsequently raised price targets, with Morgan Stanley setting $294 and Citigroup at $298.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)